The Long-Term Effects of Olmesartan Combined Amlodipine among Hypertensive Patients in a Tertiary Care Hospital – A Retrospective Study

Abstract

Introduction: Hypertension, commonly known as high blood pressure, stands as a pervasive global health concern, often referred to as the "silent killer" due to its asymptomatic nature. The management of hypertension is critical to prevent cardiovascular complications and other associated health risks. This study aimed to observe the long-term effects of olmesartan combined with amlodipine among hypertensive patients. Methods: This was a retrospective observational study conducted in the Department of Medicine, Popular Medical College Hospital, Dhaka, Bangladesh during the period from January, 2023 to December, 2023. In our study, we included 210 hypertensive patients who were divided into three groups: Group A -Patients who received Olmesartan (OM 40 mg), Group B -Patients who received Amlodipine (AML 5 mg), and Group C -Patients who received the combination of Olmesartan (OM 40 mg) and Amlodipine (AML 5 mg). Result: We found the mean age was 52.8 ± 11.3 years. Most of our patients were male (68.10%). The majority of patients in Group B had ≤140⁄90 mmHg blood pressure than the other groups at the end of our study. Patients with ≤130⁄85 mmHg, were higher in Group A. Patients with ≤130⁄80 mmHg blood pressure during the last week of the study were highest in Group C. Drowsiness/dizziness, headache, nausea/vomiting, and stomach /abdominal pain were the most common side effects. Conclusion: In our study, we discovered that Olmevas AM (OM/AML) 40/5 mg was more effective at decreasing blood pressure than either OM (Olmesartan) 40 mg or AML (Amlodipine) 5 mg. There were no unexpected or unusual safety concerns found with OM/AML combo therapy.